Gpr6 deficiency leads to a reduction of striatal cAMP and an increase of dopamine.
P-DARPP-32 concentrations are increased in the striatum of Gpr6 deficient mice.
Gpr6 deficient mice show higher basal locomotor activity.
Higher basal locomotor activity persists after haloperidol treatment.
Gpr6 deficiency reduces dyskinesia in a mouse model of Parkinson's disease.